# A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

> **NCT03665038** · PHASE3 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Post Partum Depression

## Interventions

- **DRUG:** Brexanolone

## Key facts

- **NCT ID:** NCT03665038
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-07
- **Primary completion:** 2021-01-08
- **Final completion:** 2021-01-08
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03665038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03665038, "A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03665038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*